Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expected net sales of JPY 263,000 million, Operating profit of JPY 37,000 million, Profit attributable to owners of parent of JPY 27,500 million and Basic earnings per share of JPY 120.54.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,036 JPY | +2.50% | +4.03% | +6.79% |
Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.79% | 4.4B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024